URGN
UroGen Pharma Ltd
41.20$
-1.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 94.1% | 94.9% | 98.1% | 99.0% | 97.7% | 96.6% | 95.8% | 94.3% | 91.1% | 92.8% | 93.6% | 93.2% | |
| 61.6% | 53.7% | 65.9% | 78.0% | 41.4% | 60.2% | 42.0% | 44.5% | 48.7% | 55.2% | 43.9% | 31.3% | |
| 76.1% | 77.3% | 82.2% | 85.5% | 82.7% | 82.8% | 79.1% | 75.2% | 68.6% | 60.1% | 55.8% | 42.7% | |
| 6.6% | 8.7% | 7.1% | 6.2% | 7.6% | 7.1% | 7.9% | 9.4% | 10.6% | 16.5% | 21.8% | 35.1% | |
| 2.6% | 3.2% | 3.6% | 2.6% | 2.5% | 3.2% | 3.1% | 3.4% | 4.5% | 8.2% | 8.2% | 9.7% | |
| 121.7% | 136.6% | 120.0% | 89.2% | 91.5% | 103.1% | 118.8% | 144.7% | 162.4% | 152.6% | 149.0% | 152.4% | |
| 13.3% | 17.5% | 13.1% | 12.1% | 10.9% | 16.1% | 17.0% | 22.8% | 22.8% | 23.2% | 20.0% | 24.5% | |
| 0.4% | 0.5% | 0.4% | 0.6% | 0.3% | 1.1% | 0.6% | 0.7% | 0.9% | – | 0.8% | 0.8% | |
| 2.1% | 3.7% | 3.1% | 3.0% | 1.8% | 3.8% | 5.9% | 6.5% | 5.6% | 6.1% | 6.8% | 15.8% | |
| 50.9% | 55.3% | 48.7% | 34.7% | 40.3% | 42.6% | 49.3% | 58.7% | 66.0% | 61.0% | 74.7% | 74.7% | |
| -21.7% | -36.6% | -20.0% | 10.8% | 8.5% | -3.1% | -18.8% | -44.7% | -62.4% | -52.6% | -49.0% | -52.4% | |
| -337.4% | -381.0% | -354.8% | -264.3% | -254.6% | -282.2% | -343.3% | -431.2% | -504.4% | -478.8% | -387.6% | -395.0% | |
| 16.7% | 20.3% | 16.6% | 13.1% | 14.3% | 16.5% | 19.2% | 22.9% | 26.0% | 24.6% | 19.8% | 19.9% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.